Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

CBFA2T3 (core-binding factor, runt domain, alpha subunit 2; translocated to, 3)

Written2005-10Anthony J Bais
Department of Haematology, Genetic Pathology, Flinders University, Bedford Park, Adelaide, SA 5042, Australia

(Note : for Links provided by Atlas : click)


Alias (NCBI)MTG16
HGNC Alias symbMTGR2
HGNC Alias namemyeloid translocation gene 8 and 16b
HGNC Previous namecore-binding factor, runt domain, alpha subunit 2; translocated to, 3
 CBFA2/RUNX1 translocation partner 3
LocusID (NCBI) 863
Atlas_Id 428
Location 16q24.3  [Link to chromosome band 16q24]
Location_base_pair Starts at 88874858 and ends at 88941350 bp from pter ( according to GRCh38/hg38-Dec_2013)  [Mapping CBFA2T3.png]
Local_order telomere; centromeric to CDH15 and telomeric to GALNS
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)
CBFA2T3 (16q24.3)::BLOC1S1 (12q13.2)CBFA2T3 (16q24.3)::GALNS (16q24.3)CBFA2T3 (16q24.3)::GLIS2 (16p13.3)
CBFA2T3 (16q24.3)::RUNX1 (21q22.12)KCNIP2 (10q24.32)::CBFA2T3 (16q24.3)MAP4 (3p21.31)::CBFA2T3 (16q24.3)
NFIA (1p31.3)::CBFA2T3 (16q24.3)PAX5 (9p13.2)::CBFA2T3 (16q24.3)PIEZO1 (16q24.3)::CBFA2T3 (16q24.3)
RUNX1 (21q22.12)::CBFA2T3 (16q24.3)STPG1 (1p36.11)::CBFA2T3 (16q24.3)


Description CBFA2T3 encodes two alternative transcripts, CBFA2T3A and CBFA2T3B, via the use of alternative start sites at exons 1A and 1B, respectively.
  • CBFA2T3A is 4,265-bp in length, composed of 13 exons (1A and 2 to 12) spanning approximately 130-kb of genomic DNA, and has an ORF of 1,959-bp encoding a protein of 653 amino acids.
  • CBFA2T3B is 4,034-bp in length, composed of 12 exons (1B to 12 splicing out exon 3) spanning approximately 50-kb of genomic DNA, and has an ORF of 1,701-bp encoding a protein of 567 amino acids.
  • Additional CBFA2T3C and CBFA2T3D isoforms have been identified in leukemic and HEL cell lines. CBFA2T3C encodes a protein that lacks exons 2 and 3, and CBFA2T3D is a truncated protein with out-of-frame splicing of exon 1A to exon 5.
  • The CBFA2T3A open-reading-frame (ORF) may include an additional 177 amino acids beyond the originally proposed methionine start codon.
  • The CBFA2T3B isoform contains a high-density 1-kb CpG island within and five prime to the exon 1B start site.
  • A hypothetical protein FLJ26728 located within and proximal to the CpG island transcribes antisense to CBFA2T3. Another hypothetical protein FLJ23429 transcribes antisense starting from within the first alternative intron.
  • Pseudogene None identified.


    Description ETO proteins are composed of four evolutionarily conserved domains termed nervy homology regions (NHR1 to 4) and three proline-serine-threonine (PST) rich regions. The fourth NHR region is also referred to as the zinc-finger MYND (zf myeloid-nervy-DEAF-1) domain.
  • NHR1 shares significant homology to human TATA-binding protein (TBP)-associated factor 130 (hTAF 130), hTAF 105, Drosophila accessory or activation factor TAF 110, and is often referred to as the TAF 110 domain.
  • NHR2 is a small region containing homo and heterodimerization domains and a hydrophobic heptad repeat (HHR) unit.
  • The sequence of NHR3 is unremarkable in homology and often referred to as the nervy domain.
  • The C-terminal NHR4 domain exists in numerous human, murine, Caenorhabditis elegans and Drosophila proteins, and contains a MYND zinc-finger motif. The motif is composed of CXXC and two (C-H)XXXC regions which correspond to cysteine-histidine 'knuckle structures' that are the basic building blocks of many zinc-finger proteins. The zinc-finger is common to the developmental proteins rat programmed cell death (RP-8), the human homolog programmed cell death 2 (PDCD2), deformed epidermal autoregulatory factor-1 (DEAF-1), suppressin (SPN), BLU or zinc-finger MYND domain containing 10 (ZMYND10), adenovirus 5 E1A binding protein (BS69), and CD8 beta opposite (BOP).
  • Expression CBFA2T3 is widely expressed in B-cells, blood, brain, breast, cervix, colon, eye, kidney tumor, lymph, marrow, muscle, pancreas, placenta and tonsil. CBFA2T3 exists predominantly as 4.5 and 4.2-kb transcripts along with several other minor RNAs in heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral blood leukocyte.
    Localisation All ETO members contain nuclear localization signals (NLS), some of which may be abrogated through five prime variations to enable extracellular targeting. For instance, CBFA2T1 has been detected in the cytoplasm of Purkinje cells in adult human brain, and both CBFA2T1 and CBFA2T3B have been detected in the Golgi apparatus, where they may function as cAMP-dependent protein kinase anchoring proteins. The majority of ETO proteins presumably remain in the nucleus for transcriptional regulation.
    Function CBFA2T3 has been considered to function as a transcriptional repressor via interaction with corepressor complexes.
  • The CBFA2T3A isoform oligomerizes and drags MTG8 and MTGR1 to the nucleus, oligomerizes with RUNX1-MTG16 fusion proteins in the nucleoplasm, interacts with nuclear HDACs 1 and 3, and when overexpressed accumulates at the periphery of nucleoli in characteristic rings. Because clustered arrays of inactive methylated ribosomal DNA (rDNA) repeats are also found at the nucleoli periphery, it has been speculated that CBFAT23A could be involved in methylation silencing of rDNA in the nucleolus.
  • The CBFA2T3B isoform has been shown to function in T lymphocytes as a kinase anchorage protein, and interact with cyclic nucleotide phosphodiesterases, suggesting it may function in T cell activation and inflammatory response. CBFA2T3B has been shown to function as a transcriptional repressor when tethered to a GAL4 DNA-binding domain in gene reporter assays, and inhibit the growth of breast tumor cell lines with reduced expression when ectopically expressed using retrovirus.

    CBFA2T3 has been found to interact with a novel zinc finger protein KIA00924 to mediate potent transcriptional repression as determined by CAT reporter gene assays. The presence of a zinc-finger motif common to developmental proteins suggests that CBFA2T3 might function in regulating differentiation and morphogenesis. The RP-8 and human homolog PDCD2 proteins assume a role in programmed cell death, a process essential for epithelial turnover. DEAF-1 is essential for early embryonic dorsal epidermal, eye and wing development in Drosophila. BOP encodes a muscle-restricted protein essential for cardiomyocyte differentiation and morphogenesis. BLU is a candidate tumor suppressor gene from the 3p21.3 LOH region in many human cancers, and SPN from rat functions as a potent tumor suppressor of leukemia, lymphoma and thymoma cells and tumor cells from the brain, breast, pituitary and adrenal glands.
    CBFA2T3 transcripts of CD34(+) progenitor cells have been shown to be rapidly reduced by cytokine-induced differentiation into myeloid or erythroid lineages, supporting suggestion that CBFA2T3 may function in hematopoietic differentiation. The CBFA2T3B CpG island contains several Specificity protein 1 (Sp1), homeotic, epidermal and insulin growth factor recognition sites. High conserved binding sites include GATA-1, CREB, F-1 and PKNOX1.

  • Homology The human gene CBFA2T3 is a member of the eight-twenty-one (ETO) family of proteins. The human ETO family consists of the ETO gene, also known as the myeloid translocation gene 8 (MTG8, CBFA2T1), the myeloid translocation gene related protein-1 (EHT, MTGR1, CBFA2T2), and the myeloid translocation gene 16 (MTG16, MTGR2, ZMYND4, HGNC:1537, CBFA2T3).
    Murine homologs of the ETO family include mETO (cbfa2t1h), ET0-2 (cbfa2t3h), and cbfa2t2h, the latter of which is uncharacterised. Chicken cETO and Drosophila nervy homologs have also been identified.
    The ETO protein family members and NHRs are highly homologous and conserved to each other. The CBFA2T3A and B isoforms share significant homology to MTG8 (67 and 75%, respectively) and MTGR1 (54 and 61%, respectively), and approximately 30% homology to nervy. CBFA2T3 shares 86% homology to the murine ETO-2 (cbfa2t3h), which in turn shares 75 and 60% homology to MTG8 and MTGR1, respectively, suggesting that ETO-2 is the murine homolog of CBFA2T3. MTG8 is approximately 99, 65 and 30% homologous to murine ETO, MTGR1 and nervy, respectively.


    Note None recorded.

    Implicated in

    Entity in therapy related acute myeloid leukemia (t-AML) --> CBFA2T3/ RUNX1
    Note CBFA2T3 or MTG16 was identified by molecular characterization of a second less common therapy-related AML translocation involving t(16;21). Characterization of the t(16;21) demonstrated that RUNX1-MTG16 fusion transcripts similar to RUNX1-ETO were generated
    Abnormal Protein
  • The RUNX1-MTG8, and to a lesser extent the RUNX1-MTG16, fusion transcripts of the and t(16;21) events are most recognized for their ability to function as transcriptional repressors of genes normally activated by RUNX1 through their interaction with corepressor complexes involving N-CoR, mSin3A, SMRT, and HDACs.
  • The MTG8 or CBFA2T1 gene is the most studied member of the ETO family and is additionally recognized for its ability to function independently as a nuclear transcriptional repressor through nuclear corepressor complex interaction. Gene targeting experiments demonstrating that homozygous mutant mice with an inactivating insertion of LacZ in exon 2 of the MTG8 locus resulted in massive gastrointestinal defects, have also shown that MTG8 and perhaps ETO family members are essential for gastrointestinal development .
  • Multiple NHRs of the ETO family of proteins are required and cooperate to mediate transcriptional repression. Most of the proteins that interact with NHRs have been assigned from studies of RUNX1-MTG8 and its interacting proteins. Studies originally demonstrated that MTG8s NHR2 and NHR4 were required for AML-MTG8 to inhibit RUNX1 mediated transcriptional activation and initiated the search for 'corepressor complexes' that bind to these regions. Several yeast two-hybrid systems using portions of MTG8 as bait demonstrated that specific portions of NHR2, NHR3 and NHR4 interact with the human nuclear receptor co-repressor (HuN-CoR)-mSin3A-HDAC1 corepressor complex.
  • The N-CoR protein was originally described to interact with DNA-bound nuclear receptors to repress transcription of target genes through recruitment of HDAC containing complexes and was latter shown to form complexes with mammalian Sin3 to alter chromatin structure and mediate transcriptional repression via nuclear receptors and oncoregulatory proteins.
  • A similar yeast two-hybrid approach also established that the corepressor silencing mediator of retinoic acid and thyroid hormone receptors (SMRT) interacts with MTG8. The zinc-finger NHR4 is necessary but not sufficient for repression and interaction with SMRT and N-CoR in vitro. The direct physical association of MTG8 with corepressors is more complex. A 'core-repressor domain' containing NHR2 and the neighboring amino and carboxy terminal sequences was defined and found to be the strongest region of interaction with mSin3a and transcriptional repression.
  • In the RUNX1-MTG8 translocation product associated with myeloid malignancies, the transactivation domain of the RUNX1 gene, which normally binds the transcriptional coactivators p300-CBP, is replaced by almost the entire MTG8 protein. The resultant fusion protein recruits a corepressor complex containing HDAC activity instead of the coactivators p300-CBP to RUNX1 responsive genes giving rise to leukemia. The repression activity of the MTG8 protein was demonstrated from a GAL4 DNA binding domain (DBD) MTG8 fusion construct which mediated strong repression through multimerized GAL4 binding sites upstream of a minimal promoter driving a reporter gene. Consistent with a mechanism involving MTG8 and HDAC corepressor interactions, the repressive effect of MTG8 was partially overcome with the addition of the HDAC inhibitor trichostatin A (TSA). Mutational studies of RUNX1-MTG8 have shown that NHR4 is responsible for repression of the multidrug resistance 1 promoter.
  • MTG8 has also been shown to interact with the Dentato-rubral and Pallido-luysian atrophy gene product, atrophin-1, in a yeast two-hybrid assay. Both Dentato-rubral and Pallido-luysian atrophies are neurodegenerative disorders caused by expansion of polyglutamine tracts.
  • Several other transcriptional repressors have been shown to interact with MTG8. The promyelocytic leukemia zinc-finger ( PLZF), a transcriptional repressor found in hematopoietic cells and down-regulated during differentiation of myeloid cell lines was shown to exhibit enhanced repressor activity when interacting with MTG8 in 293T cells and assayed using a reporter plasmid containing four copies of a high affinity PLZF binding site linked to firefly luciferase. The ability of MTG8 to enhance repression was abolished upon addition of HDAC inhibitors TSA and sodium butyrate, suggesting that the MTG8 enhanced repression by PLZF is also mediated through the recruitment of HDACs.
  • The Growth factor independence-1 (Gfi-1), a HDAC interacting transcriptional repressor found in hematopoietic cells, was shown in vitro and in vivo to interact with NHR1 and NHR2 of MTG8. These interactions together with gene targeting experiments demonstrating MTG8s involvement in gastrointestinal development, the well established interactions with corepressor complexes, and the presence of a zinc-finger motif common to numerous developmental proteins, suggests that ETO family members including CBFA2T3 may play function in regulating cell cycle transcription during differentiation and proliferation of specific cell type-lineages, for example hematopoietic cells as indicated for MTG8.
    Entity Loss of heterozygosity (LOH) of 16q22-qter in breast cancer, prostate cancer, and several other cancers
    Note This region is frequently deleted in several human cancers causing loss of heterozygosity. The 16q24.3 region including CBFA2T3 spans approximately 3-Mb from the marker D16S498 to the telomere and contains at least two smallest regions of overlap (SROs). These SROs are most frequently deleted in early and late stage breast cancer and in prostate cancer. Loss of normal function of CBFA2T3 may be a key event in the early stage of breast cancer. LOH on the whole 16q22-qter region is frequently detected in breast and prostate cancer.
    CBFA2T3B is a potential tumor suppressor gene affected by LOH, aberrant gene expression and promoter methylation in breast cancer. Quantitative gene expression analysis of 78 genes in the 16q24.3 region demonstrated that CBFA2T3 was the only gene with an aberrant expression profile distinctly similar to the known tumor suppressors SYK and CDKN2A. 68 genes displayed normal expression, six displayed mildly aberrant expression (DPEP1, CDH15, Hs.17074, Hs.189419, SLC7A5 and AA994450), one displayed excessively reduced expression (CA5A), and two displayed moderately aberrant expression (CYBA and FBX031). The CBFA2T3B promoter region displays aberrant hypo and hypermethylation in breast tumor cell lines and primary breast tumor samples in correlation with aberrant gene expression.
    Disease 16q22-qter LOH is detected in bilateral breast cancer and ductal lavage, in rare inflammatory breast cancer, and in several other cancers, including central nervous system neuroectodermal and primary ependymomas, colorectal liver metastases, gastric tumor, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung tumor, nasopharyngeal tumor, ovarian tumor, rhabdomyosarcoma, and Wilms' tumor. 16q22-qter LOH in ovarian, hepatocellular and particularly breast and prostate cancers, exhibit similar SROs, suggesting common molecular pathways are affected.


    Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
    Agathanggelou A, Dallol A, Zöchbauer-Müller S, Morrissey C, Honorio S, Hesson L, Martinsson T, Fong KM, Kuo MJ, Yuen PW, Maher ER, Minna JD, Latif F
    Oncogene. 2003 ; 22 (10) : 1580-1588.
    PMID 12629521
    Characterisation of transcriptionally active and inactive chromatin domains in neurons.
    Akhmanova A, Verkerk T, Langeveld A, Grosveld F, Galjart N
    Journal of cell science. 2000 ; 113 Pt 24 : 4463-4474.
    PMID 11082040
    Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression.
    Alland L, Muhle R, Hou H Jr, Potes J, Chin L, Schreiber-Agus N, DePinho RA
    Nature. 1997 ; 387 (6628) : 49-55.
    PMID 9139821
    ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain.
    Amann JM, Nip J, Strom DK, Lutterbach B, Harada H, Lenny N, Downing JR, Meyers S, Hiebert SW
    Molecular and cellular biology. 2001 ; 21 (19) : 6470-6483.
    PMID 11533236
    The conserved Mynd domain of BS69 binds cellular and oncoviral proteins through a common PXLXP motif.
    Ansieau S, Leutz A
    The Journal of biological chemistry. 2002 ; 277 (7) : 4906-4910.
    PMID 11733528
    A-kinase anchoring proteins interact with phosphodiesterases in T lymphocyte cell lines.
    Asirvatham AL, Galligan SG, Schillace RV, Davey MP, Vasta V, Beavo JA, Carr DW
    Journal of immunology (Baltimore, Md. : 1950). 2004 ; 173 (8) : 4806-4814.
    PMID 15470020
    Aberrant CBFA2T3B gene promoter methylation in breast tumors.
    Bais AJ, Gardner AE, McKenzie OL, Callen DF, Sutherland GR, Kremmidiotis G
    Molecular cancer. 2004 ; 3 : page 22.
    PMID 15301688
    CBFA2T1, a gene rearranged in human leukemia, is a member of a multigene family.
    Calabi F, Cilli V
    Genomics. 1998 ; 52 (3) : 332-341.
    PMID 9790752
    Gene targeting reveals a crucial role for MTG8 in the gut.
    Calabi F, Pannell R, Pavloska G
    Molecular and cellular biology. 2001 ; 21 (16) : 5658-5666.
    PMID 11463846
    Allelic loss of chromosomes 16q and 10q in human prostate cancer.
    Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB
    Proceedings of the National Academy of Sciences of the United States of America. 1990 ; 87 (22) : 8751-8755.
    PMID 1978938
    A transcriptional co-repressor that interacts with nuclear hormone receptors.
    Chen JD, Evans RM
    Nature. 1995 ; 377 (6548) : 454-457.
    PMID 7566127
    Frequent allelic loss on chromosomes 4q and 16q associated with human hepatocellular carcinoma in Taiwan.
    Chou YH, Chung KC, Jeng LB, Chen TC, Liaw YF
    Cancer letters. 1998 ; 123 (1) : 1-6.
    PMID 9461010
    The role of promyelocytic leukemia zinc finger and promyelocytic leukemia in leukemogenesis and development.
    Costoya JA, Pandolfi PP
    Current opinion in hematology. 2001 ; 8 (4) : 212-217.
    PMID 11561158
    The ETO (MTG8) gene family.
    Davis JN, McGhee L, Meyers S
    Gene. 2003 ; 303 : 1-10.
    PMID 12559562
    ETO-2, a new member of the ETO-family of nuclear proteins.
    Davis JN, Williams BJ, Herron JT, Galiano FJ, Meyers S
    Oncogene. 1999 ; 18 (6) : 1375-1383.
    PMID 10022820
    Genetic profiling of colorectal cancer liver metastases by combined comparative genomic hybridization and G-banding analysis.
    Diep CB, Parada LA, Teixeira MR, Eknaes M, Nesland JM, Johansson B, Lothe RA
    Genes, chromosomes & cancer. 2003 ; 36 (2) : 189-197.
    PMID 12508247
    Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt.
    Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H
    Blood. 1992 ; 80 (7) : 1825-1831.
    PMID 1391946
    The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor.
    Erickson PF, Robinson M, Owens G, Drabkin HA
    Cancer research. 1994 ; 54 (7) : 1782-1786.
    PMID 8137293
    Identification of homeotic target genes in Drosophila melanogaster including nervy, a proto-oncogene homologue.
    Feinstein PG, Kornfeld K, Hogness DS, Mann RS
    Genetics. 1995 ; 140 (2) : 573-586.
    PMID 7498738
    EHT, a new member of the MTG8/ETO gene family, maps on 20q11 region and is deleted in acute myeloid leukemias.
    Fracchiolla NS, Colombo G, Finelli P, Maiolo AT, Neri A
    Blood. 1998 ; 92 (9) : 3481-3484.
    PMID 9787195
    MTG8 proto-oncoprotein interacts with the regulatory subunit of type II cyclic AMP-dependent protein kinase in lymphocytes.
    Fukuyama T, Sueoka E, Sugio Y, Otsuka T, Niho Y, Akagi K, Kozu T
    Oncogene. 2001 ; 20 (43) : 6225-6232.
    PMID 11593431
    The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family.
    Gamou T, Kitamura E, Hosoda F, Shimizu K, Shinohara K, Hayashi Y, Nagase T, Yokoyama Y, Ohki M
    Blood. 1998 ; 91 (11) : 4028-4037.
    PMID 9596646
    Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO.
    Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA
    Molecular and cellular biology. 1998 ; 18 (12) : 7185-7191.
    PMID 9819405
    Allelic imbalance mapping of chromosome 16 shows two regions of common deletion in prostate adenocarcinoma.
    Godfrey TE, Cher ML, Chhabra V, Jensen RH
    Cancer genetics and cytogenetics. 1997 ; 98 (1) : 36-42.
    PMID 9309116
    Bop encodes a muscle-restricted protein containing MYND and SET domains and is essential for cardiac differentiation and morphogenesis.
    Gottlieb PD, Pierce SA, Sims RJ, Yamagishi H, Weihe EK, Harriss JV, Maika SD, Kuziel WA, King HL, Olson EN, Nakagawa O, Srivastava D
    Nature genetics. 2002 ; 31 (1) : 25-32.
    PMID 11923873
    Allelic imbalance on 16q in small, unifocal hepatocellular carcinoma: correlation with HBV and HCV infections and cellular proliferation rate.
    Gramantieri L, Trerè D, Pession A, Piscaglia F, Masi L, Gaiani S, Mazziotti A, Bolondi L
    Digestive diseases and sciences. 2000 ; 45 (2) : 306-311.
    PMID 10711443
    The Gfi-1 proto-oncoprotein contains a novel transcriptional repressor domain, SNAG, and inhibits G1 arrest induced by interleukin-2 withdrawal.
    Grimes HL, Chan TO, Zweidler-McKay PA, Tong B, Tsichlis PN
    Molecular and cellular biology. 1996 ; 16 (11) : 6263-6272.
    PMID 8887656
    DEAF-1, a novel protein that binds an essential region in a Deformed response element.
    Gross CT, McGinnis W
    The EMBO journal. 1996 ; 15 (8) : 1961-1970.
    PMID 8617243
    Loss of heterozygosity in chromosomal region 16q24.3 associated with progression of prostate cancer.
    Härkö P, Kyllönen AP, Nordling S, Vihko P
    The Prostate. 2005 ; 62 (3) : 267-274.
    PMID 15389780
    Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor.
    Hörlein AJ, Näär AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Söderström M, Glass CK
    Nature. 1995 ; 377 (6548) : 397-404.
    PMID 7566114
    Allelic imbalance in selected chromosomal regions in ovarian cancer.
    Hansen LL, Jensen LL, Dimitrakakis C, Michalas S, Gilbert F, Barber HR, Overgaard J, Arzimanoglou II
    Cancer genetics and cytogenetics. 2002 ; 139 (1) : 1-8.
    PMID 12547149
    Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.
    Heibert SW, Lutterbach B, Durst K, Wang L, Linggi B, Wu S, Wood L, Amann J, King D, Hou Y
    Cancer chemotherapy and pharmacology. 2001 ; 48 Suppl 1 : S31-S34.
    PMID 11587363
    A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression.
    Heinzel T, Lavinsky RM, Mullen TM, Söderstrom M, Laherty CD, Torchia J, Yang WM, Brard G, Ngo SD, Davie JR, Seto E, Eisenman RN, Rose DW, Glass CK, Rosenfeld MG
    Nature. 1997 ; 387 (6628) : 43-48.
    PMID 9139820
    Multiple regions of ETO cooperate in transcriptional repression.
    Hildebrand D, Tiefenbach J, Heinzel T, Grez M, Maurer AB
    The Journal of biological chemistry. 2001 ; 276 (13) : 9889-9895.
    PMID 11150306
    Molecular cloning and functional analysis of Drosophila TAF110 reveal properties expected of coactivators.
    Hoey T, Weinzierl RO, Gill G, Chen JL, Dynlacht BD, Tjian R
    Cell. 1993 ; 72 (2) : 247-260.
    PMID 7678780
    The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t (16; 21)-positive myeloid malignancies.
    Hoogeveen AT, Rossetti S, Stoyanova V, Schonkeren J, Fenaroli A, Schiaffonati L, van Unen L, Sacchi N
    Oncogene. 2002 ; 21 (43) : 6703-6712.
    PMID 12242670
    Bop: a new T-cell-restricted gene located upstream of and opposite to mouse CD8b.
    Hwang I, Gottlieb PD
    Immunogenetics. 1995 ; 42 (5) : 353-361.
    PMID 7590968
    AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation.
    Ibañez V, Sharma A, Buonamici S, Verma A, Kalakonda S, Wang J, Kadkol S, Saunthararajah Y
    Cancer research. 2004 ; 64 (13) : 4547-4554.
    PMID 15231665
    Lithium treatment in ovo: effects on embryonic heart rate, natural death of ciliary ganglion neurons, and brain expression of a highly conserved chicken homolog of human MTG8/ETO.
    Ikonomov OC, Petrov T, Soden K, Shisheva A, Manji HK
    Brain research. Developmental brain research. 2000 ; 123 (1) : 13-24.
    PMID 11020546
    The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG8(ETO/CDR) family, MTGR1.
    Kitabayashi I, Ida K, Morohoshi F, Yokoyama A, Mitsuhashi N, Shimizu K, Nomura N, Hayashi Y, Ohki M
    Molecular and cellular biology. 1998 ; 18 (2) : 846-858.
    PMID 9447981
    CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3.
    Kochetkova M, McKenzie OL, Bais AJ, Martin JM, Secker GA, Seshadri R, Powell JA, Hinze SJ, Gardner AE, Spendlove HE, O'Callaghan NJ, Cleton-Jansen AM, Cornelisse C, Whitmore SA, Crawford J, Kremmidiotis G, Sutherland GR, Callen DF
    Cancer research. 2002 ; 62 (16) : 4599-4604.
    PMID 12183414
    Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions.
    Latil A, Cussenot O, Fournier G, Driouch K, Lidereau R
    Cancer research. 1997 ; 57 (6) : 1058-1062.
    PMID 9067271
    Loss of heterozygosity at chromosomes 3, 6, 8, 11, 16, and 17 in ovarian cancer: correlation to clinicopathological variables.
    Launonen V, Mannermaa A, Stenbäck F, Kosma VM, Puistola U, Huusko P, Anttila M, Bloigu R, Saarikoski S, Kauppila A, Winqvist R
    Cancer genetics and cytogenetics. 2000 ; 122 (1) : 49-54.
    PMID 11104033
    Functional domains of the t(8;21) fusion protein, AML-1/ETO.
    Lenny N, Meyers S, Hiebert SW
    Oncogene. 1995 ; 11 (9) : 1761-1769.
    PMID 7478604
    Evidence of chromosome regions and gene involvement in inflammatory breast cancer.
    Lerebours F, Bertheau P, Bieche I, Driouch K, De The H, Hacene K, Espie M, Marty M, Lidereau R
    International journal of cancer. Journal international du cancer. 2002 ; 102 (6) : 618-622.
    PMID 12448004
    The Leukemia-associated ETO homologues are differently expressed during hematopoietic differentiation.
    Lindberg SR, Olsson A, Persson AM, Olsson I
    Experimental hematology. 2005 ; 33 (2) : 189-198.
    PMID 15676213
    The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein.
    Lutterbach B, Sun D, Schuetz J, Hiebert SW
    Molecular and cellular biology. 1998 ; 18 (6) : 3604-3611.
    PMID 9584201
    The adenovirus E1A binding protein BS69 is a corepressor of transcription through recruitment of N-CoR.
    Masselink H, Bernards R
    Oncogene. 2000 ; 19 (12) : 1538-1546.
    PMID 10734313
    Clinical significance of chromosome 8p, 10q, and 16q deletions in prostate cancer.
    Matsuyama H, Pan Y, Yoshihiro S, Kudren D, Naito K, Bergerheim US, Ekman P
    The Prostate. 2003 ; 54 (2) : 103-111.
    PMID 12497583
    A third Wilms' tumor locus on chromosome 16q.
    Maw MA, Grundy PE, Millow LJ, Eccles MR, Dunn RS, Smith PJ, Feinberg AP, Law DJ, Paterson MC, Telzerow PE
    Cancer research. 1992 ; 52 (11) : 3094-3098.
    PMID 1317258
    Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism.
    McGhee L, Bryan J, Elliott L, Grimes HL, Kazanjian A, Davis JN, Meyers S
    Journal of cellular biochemistry. 2003 ; 89 (5) : 1005-1018.
    PMID 12874834
    AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein.
    Melnick A, Carlile GW, McConnell MJ, Polinger A, Hiebert SW, Licht JD
    Blood. 2000 ; 96 (12) : 3939-3947.
    PMID 11090081
    Indirect and direct disruption of transcriptional regulation in cancer: E2F and AML-1.
    Meyers S, Hiebert SW
    Critical reviews in eukaryotic gene expression. 1995 ; 5 (3-4) : 365-383.
    PMID 8834231
    The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript.
    Miyoshi H, Kozu T, Shimizu K, Enomoto K, Maseki N, Kaneko Y, Kamada N, Ohki M
    The EMBO journal. 1993 ; 12 (7) : 2715-2721.
    PMID 8334990
    t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1.
    Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M
    Proceedings of the National Academy of Sciences of the United States of America. 1991 ; 88 (23) : 10431-10434.
    PMID 1720541
    Chromosome band 16q24 is frequently deleted in human gastric cancer.
    Mori Y, Matsunaga M, Abe T, Fukushige S, Miura K, Sunamura M, Shiiba K, Sato M, Nukiwa T, Horii A
    British journal of cancer. 1999 ; 80 (3-4) : 556-562.
    PMID 10408866
    Cloning and gene mapping of the mouse homologue of the CBFA2T1 gene associated with human acute myeloid leukemia.
    Niwa-Kawakita M, Miyoshi H, Gotoh O, Matsushima Y, Nishimura M, Shisa H, Ohki M
    Genomics. 1995 ; 29 (3) : 755-759.
    PMID 8575770
    Identification of mRNAs associated with programmed cell death in immature thymocytes.
    Owens GP, Hahn WE, Cohen JJ
    Molecular and cellular biology. 1991 ; 11 (8) : 4177-4188.
    PMID 2072913
    Regulation by homeoproteins: a comparison of deformed-responsive elements.
    Pederson JA, LaFollette JW, Gross C, Veraksa A, McGinnis W, Mahaffey JW
    Genetics. 2000 ; 156 (2) : 677-686.
    PMID 11014815
    Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes.
    Powell JA, Gardner AE, Bais AJ, Hinze SJ, Baker E, Whitmore S, Crawford J, Kochetkova M, Spendlove HE, Doggett NA, Sutherland GR, Callen DF, Kremmidiotis G
    Genomics. 2002 ; 80 (3) : 303-310.
    PMID 12213200
    When more is less: pathogenesis of glutamine repeat neurodegenerative diseases.
    Ross CA
    Neuron. 1995 ; 15 (3) : 493-496.
    PMID 7546729
    The MTG proteins: chromatin repression players with a passion for networking.
    Rossetti S, Hoogeveen AT, Sacchi N
    Genomics. 2004 ; 84 (1) : 1-9.
    PMID 15203199
    Subcellular localization of the oncoprotein MTG8 (CDR/ETO) in neural cells.
    Sacchi N, Tamanini F, Willemsen R, Denis-Donini S, Campiglio S, Hoogeveen AT
    Oncogene. 1998 ; 16 (20) : 2609-2615.
    PMID 9632137
    Fine mapping of Wilms' tumors with 16q loss of heterozygosity localizes the putative tumor suppressor gene to a region of 6.7 megabases.
    Safford SD, Goyeau D, Freemerman AJ, Bentley R, Everett ML, Grundy PE, Skinner MA
    Annals of surgical oncology. 2003 ; 10 (2) : 136-143.
    PMID 12620908
    Loss of heterozygosity on chromosome 16 in hepatocellular carcinoma.
    Sakai K, Nagahara H, Abe K, Obata H
    Journal of gastroenterology and hepatology. 1992 ; 7 (3) : 288-292.
    PMID 1351753
    Identification of a 910-kb region of common allelic loss in chromosome bands 16q24.1-q24.2 in human lung cancer.
    Sato M, Mori Y, Sakurada A, Fukushige S, Ishikawa Y, Tsuchiya E, Saito Y, Nukiwa T, Fujimura S, Horii A
    Genes, chromosomes & cancer. 1998 ; 22 (1) : 1-8.
    PMID 9591628
    Accumulation of genetic alterations and progression of primary breast cancer.
    Sato T, Akiyama F, Sakamoto G, Kasumi F, Nakamura Y
    Cancer research. 1991 ; 51 (21) : 5794-5799.
    PMID 1682035
    PDCD2 is a negative regulator of HCF-1 (C1).
    Scarr RB, Sharp PA
    Oncogene. 2002 ; 21 (34) : 5245-5254.
    PMID 12149646
    Identification and characterization of myeloid translocation gene 16b as a novel a kinase anchoring protein in T lymphocytes.
    Schillace RV, Andrews SF, Liberty GA, Davey MP, Carr DW
    Journal of immunology (Baltimore, Md. : 1950). 2002 ; 168 (4) : 1590-1599.
    PMID 11823486
    Zinc mining for protein domains.
    Schwabe JW, Klug A
    Nature structural biology. 1994 ; 1 (6) : 345-349.
    PMID 7664042
    Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers.
    Suzuki H, Komiya A, Emi M, Kuramochi H, Shiraishi T, Yatani R, Shimazaki J
    Genes, chromosomes & cancer. 1996 ; 17 (4) : 225-233.
    PMID 8946204
    Loss of heterozygosity on 6q, 16q, and 17p in human central nervous system primitive neuroectodermal tumors.
    Thomas GA, Raffel C
    Cancer research. 1991 ; 51 (2) : 639-643.
    PMID 1670763
    Allele loss on chromosome 16 associated with progression of human hepatocellular carcinoma.
    Tsuda H, Zhang WD, Shimosato Y, Yokota J, Terada M, Sugimura T, Miyamura T, Hirohashi S
    Proceedings of the National Academy of Sciences of the United States of America. 1990 ; 87 (17) : 6791-6794.
    PMID 2168560
    DEAF-1 function is essential for the early embryonic development of Drosophila.
    Veraksa A, Kennison J, McGinnis W
    Genesis (New York, N.Y. : 2000). 2002 ; 33 (2) : 67-76.
    PMID 12112874
    Allelotype of pediatric rhabdomyosarcoma.
    Visser M, Sijmons C, Bras J, Arceci RJ, Godfried M, Valentijn LJ, Voûte PA, Baas F
    Oncogene. 1997 ; 15 (11) : 1309-1314.
    PMID 9315099
    ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.
    Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM
    Proceedings of the National Academy of Sciences of the United States of America. 1998 ; 95 (18) : 10860-10865.
    PMID 9724795
    Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells.
    Wang J, Saunthararajah Y, Redner RL, Liu JM
    Cancer research. 1999 ; 59 (12) : 2766-2769.
    PMID 10383127
    Cervical metastases of head and neck squamous cell carcinoma correlate with loss of heterozygosity on chromosome 16q.
    Wang X, Gleich L, Pavelic ZP, Li YQ, Gale N, Hunt S, Gluckman JL, Stambrook PJ
    International journal of oncology. 1999 ; 14 (3) : 557-561.
    PMID 10024691
    Atrophin-1, the dentato-rubral and pallido-luysian atrophy gene product, interacts with ETO/MTG8 in the nuclear matrix and represses transcription.
    Wood JD, Nucifora FC Jr, Duan K, Zhang C, Wang J, Kim Y, Schilling G, Sacchi N, Liu JM, Ross CA
    The Journal of cell biology. 2000 ; 150 (5) : 939-948.
    PMID 10973986
    Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma.
    Yakicier MC, Legoix P, Vaury C, Gressin L, Tubacher E, Capron F, Bayer J, Degott C, Balabaud C, Zucman-Rossi J
    Oncogene. 2001 ; 20 (37) : 5232-5238.
    PMID 11526514
    Novel chromosomal alterations detected in primary nasopharyngeal carcinoma by comparative genomic hybridization.
    Yan J, Fang Y, Liang Q, Huang Y, Zeng Y
    Chinese medical journal. 2001 ; 114 (4) : 418-421.
    PMID 11780468
    Loss of heterozygosity in ductal lavage for breast tumor and the contralateral breast.
    Yonekura Y, Yamamoto D, Okugawa H, Tanaka K, Kamiyama Y
    Oncology reports. 2005 ; 13 (4) : 739-743.
    PMID 15756451
    Oligomerization of ETO is obligatory for corepressor interaction.
    Zhang J, Hug BA, Huang EY, Chen CW, Gelmetti V, Maccarana M, Minucci S, Pelicci PG, Lazar MA
    Molecular and cellular biology. 2001 ; 21 (1) : 156-163.
    PMID 11113190
    Frequent loss of heterozygosity on chromosomes 16 and 4 in human hepatocellular carcinoma.
    Zhang WD, Hirohashi S, Tsuda H, Shimosato Y, Yokota J, Terada M, Sugimura T
    Japanese journal of cancer research : Gann. 1990 ; 81 (2) : 108-111.
    PMID 1970554
    Comparative genomic hybridization detects losses of chromosomes 22 and 16 as the most common recurrent genetic alterations in primary ependymomas.
    Zheng PP, Pang JC, Hui AB, Ng HK
    Cancer genetics and cytogenetics. 2000 ; 122 (1) : 18-25.
    PMID 11104027


    This paper should be referenced as such :
    Bais, AJ
    CBFA2T3 (core-binding factor, runt domain, alpha subunit 2; translocated to, 3)
    Atlas Genet Cytogenet Oncol Haematol. 2006;10(2):70-76.
    Free journal version : [ pdf ]   [ DOI ]

    Other Leukemias implicated (Data extracted from papers in the Atlas) [ 8 ]
      21q22 rearrangements (RUNX1) in treatment related leukemia
    inv(16)(p13q24) CBFA2T3::GLIS2
    t(16;21)(q24;q22) RUNX1::CBFA2T3
    Therapy-Related Hematopoietic Neoplasia
    t(1;16)(p31;q24) NFIA::CBFA2T3
    t(9;16)(p13;q24) PAX5::CBFA2T3
    t(14;16)(q32;q24) IGH::CBFA2T3
    t(16;16)(q24;q24) CBFA2T3::ACSF3

    External links

    HGNC (Hugo)CBFA2T3   1537
    Entrez_Gene (NCBI)CBFA2T3    CBFA2/RUNX1 partner transcriptional co-repressor 3
    AliasesETO2; MTG16; MTGR2; RUNX1T3; 
    GeneCards (Weizmann)CBFA2T3
    Ensembl hg19 (Hinxton)ENSG00000129993 [Gene_View]
    Ensembl hg38 (Hinxton)ENSG00000129993 [Gene_View]  ENSG00000129993 [Sequence]  chr16:88874858-88941350 [Contig_View]  CBFA2T3 [Vega]
    ICGC DataPortalENSG00000129993
    TCGA cBioPortalCBFA2T3
    AceView (NCBI)CBFA2T3
    Genatlas (Paris)CBFA2T3
    SOURCE (Princeton)CBFA2T3
    Genetics Home Reference (NIH)CBFA2T3
    Genomic and cartography
    GoldenPath hg38 (UCSC)CBFA2T3  -     chr16:88874858-88941350 -  16q24.3   [Description]    (hg38-Dec_2013)
    GoldenPath hg19 (UCSC)CBFA2T3  -     16q24.3   [Description]    (hg19-Feb_2009)
    GoldenPathCBFA2T3 - 16q24.3 [CytoView hg19]  CBFA2T3 - 16q24.3 [CytoView hg38]
    Genome Data Viewer NCBICBFA2T3 [Mapview hg19]  
    Gene and transcription
    Genbank (Entrez)AB010419 AB010420 AF052220 AK090985 AK097904
    RefSeq transcript (Entrez)NM_005187 NM_175931
    Consensus coding sequences : CCDS (NCBI)CBFA2T3
    Gene ExpressionCBFA2T3 [ NCBI-GEO ]   CBFA2T3 [ EBI - ARRAY_EXPRESS ]   CBFA2T3 [ SEEK ]   CBFA2T3 [ MEM ]
    Gene Expression Viewer (FireBrowse)CBFA2T3 [ Firebrowse - Broad ]
    GenevisibleExpression of CBFA2T3 in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
    BioGPS (Tissue expression)863
    GTEX Portal (Tissue expression)CBFA2T3
    Human Protein AtlasENSG00000129993-CBFA2T3 [pathology]   [cell]   [tissue]
    Protein : pattern, domain, 3D structure
    Domain families : Pfam (Sanger)
    Domain families : Pfam (NCBI)
    Conserved Domain (NCBI)CBFA2T3
    Human Protein Atlas [tissue]ENSG00000129993-CBFA2T3 [tissue]
    Protein Interaction databases
    Ontologies - Pathways
    PubMed56 Pubmed reference(s) in Entrez
    GeneRIFsGene References Into Functions (Entrez)
    REVIEW articlesautomatic search in PubMed
    Last year publicationsautomatic search in PubMed

    Search in all EBI   NCBI

    © Atlas of Genetics and Cytogenetics in Oncology and Haematology
    indexed on : Fri Oct 8 21:14:12 CEST 2021

    Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

    For comments and suggestions or contributions, please contact us